Details:
Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology
Lead Product(s): CTX-101
Therapeutic Area: Dermatology Product Name: CTX-101
Highest Development Status: Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2020